RE:one more thing before I get back to the office...I agree Mike, there are many things that don't add up here. The partnering with Ipsen is significant, I expect they were fully detailed in their due diligence before spending 10 mil. This would be magnified even further since the failure with Endo, likely with a fine tooth comb. Why would they invest if there were concerns with the efficacy or safety.
Valid point on the office space rental but don't forget that previous management built a $25mil vaccine plant which produces nothing but an expense.
Different management but this does demonstrate it can happen.